骨髓增生异常综合征。
Myelodysplastic syndromes.
机构信息
Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109, USA.
出版信息
Annu Rev Med. 2010;61:345-58. doi: 10.1146/annurev.med.051308.132852.
Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death. The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation.
骨髓增生异常综合征（MDS）是一组以造血干细胞功能障碍为特征的疾病，表现为外周血计数减少。大多数 MDS 患者表现出与贫血相关的症状；然而，出血和感染是最常见的死亡原因。诊断的中位年龄为 72 岁，中位生存时间为 2.5 年。来那度胺、阿扎胞苷和地西他滨都是 FDA 批准用于治疗 MDS 的药物；然而，MDS 的唯一潜在治愈方法仍然是干细胞移植。
Zotero 插件